reports
TMC Welcomes U.S. Executive Order to Expedite Permitting and Evaluate ...
TMC Welcomes U.S. Executive Order to Expedite Permitting and Evaluate Offtake of Critical Minerals from Nodules in the High Seas Entitled ‘Unleashing America’s Offshore Critical Minerals and Resources’, the Executive Order directs Commerce Secretary Lutnick to expedite deep seabed mineral exploration licenses and commercial recovery permits in international waters under the existing U.S. seabed mining codeThe Order also directs the Secretaries of Defense and Energy to address the feasibility of using the National Defense Stockpile for nodule-derived minerals and of entering into offtake agr...
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Contro...
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical com...
Creative Realities Awarded Menu Board and Drive-Through Digital Transf...
Creative Realities Awarded Menu Board and Drive-Through Digital Transformation Project by Upscale QSR Chain Nationwide Digital Signage Project to Support Company’s Innovation Strategy – Enhancing Customer Experience, Driving Real-Time Promotions, and Improving Throughput LOUISVILLE, Ky., April 22, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (NASDAQ: CREX) (the “Company” or “CRI), a leading provider of digital signage and media solutions for the food and beverage industry, has been selected by a well-known, upscale Quick Service Restaurant (QSR) chain, with over 1,000 locations acr...
Rutger Bosland, Pioneering Engineer and Technical Lead on Development ...
Rutger Bosland, Pioneering Engineer and Technical Lead on Development of TMC’s Nodule Collection System, Joins Company to Drive Commercial Readiness Rutger Bosland, the engineer and technical lead who oversaw the design, build and successful test deployment of Allseas’ integrated nodule collection system, joins TMC to lead offshore innovation and scale its technologies for commercial productionAs Chief Innovation and Offshore Technology Officer (CIOTO), Rutger will focus on the Company’s efforts to optimize the performance of our commercial scale nodule collection system to meet our product...
Creative Realities Announces Participation in Upcoming Planet MicroCap...
Creative Realities Announces Participation in Upcoming Planet MicroCap Event LOUISVILLE, Ky., April 14, 2025 (GLOBE NEWSWIRE) -- (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: ), a leading provider of digital signage and media solutions, today announced that it will participate in the upcoming Planet MicroCap Showcase Conference in Las Vegas on April 23 and 24, 2025. Management will provide a general presentation, to be webcast live, on April 23 at 4:00 pm Pacific Time and host one-on-one meetings with investors all day on April 24. Individuals attending the conference are enco...
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of D...
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company’s board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board member. “We’re thrilled to welcome Richard to our board,” said Richard A. Mill...
Pactiv Evergreen Inc. Announces Receipt of All Required Regulatory App...
Pactiv Evergreen Inc. Announces Receipt of All Required Regulatory Approvals for Planned Acquisition by Novolex LAKE FOREST, Ill., March 28, 2025 (GLOBE NEWSWIRE) -- Pactiv Evergreen Inc. (“Pactiv Evergreen” or the “Company”) (NASDAQ: PTVE) today announced that all required regulatory approvals have been received in connection with the Company’s previously announced definitive agreement to be acquired by Novolex® for $18.00 per share in cash. As a result, the transaction is now expected to close on April 1, 2025, subject to satisfaction of other customary closing conditions. Upon the ...
TMC Announces Fourth Quarter and Full Year 2024 Results
TMC Announces Fourth Quarter and Full Year 2024 Results NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or “the Company”), an explorer of the world’s largest undeveloped resource of critical metals for building infrastructure, power generation, transmission, and batteries, today provided a corporate update and fourth quarter and full year financial results for the period ended December 31, 2024. Q4 and FY 2024 Financial Highlights Current liquidity available from our cash on hand and our credit facilities of approximately $43 million as of d...
The Metals Company to Apply for Permits under Existing U.S. Mining Cod...
The Metals Company to Apply for Permits under Existing U.S. Mining Code for Deep-Sea Minerals in the High Seas in Second Quarter of 2025 Following successful mining tests by U.S. consortia and pioneering environmental impact assessment by the National Oceanic and Atmospheric Administration (NOAA) in the Clarion Clipperton Zone (CCZ) in the 1970s, the United States Congress passed the Deep Seabed Hard Mineral Resources Act (DSHMRA) in 1980 to enable exploration and commercial recovery of deep-sea minerals in the high seasDSHMRA, along with its implementing regulations completed by NOAA in 19...
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Qua...
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and Novel Mechanism of Action Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Corv...
Creative Realities Completes SOC 2 Type 1 Compliance Audit Process
Creative Realities Completes SOC 2 Type 1 Compliance Audit Process This confirms CRI as a SaaS provider that ensures security, stability, and privacy in its products. LOUISVILLE, Ky., March 25, 2025 (GLOBE NEWSWIRE) -- ("Creative Realities," "CRI," or the "Company") (NASDAQ: ), a leading provider of digital signage and media solutions, is pleased to announce the successful completion of its Systems and Organizations Controls (SOC) 2 Type 1 audit. This audit achieved compliance with the leading industry standards for customer data security. This report shows CRI’s ongoing commitment t...
The Metals Company Announces Fourth Quarter and Full Year 2024 Corpora...
The Metals Company Announces Fourth Quarter and Full Year 2024 Corporate Update Conference Call for Thursday, March 27, 2025 NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or the “Company”), an explorer of the world’s largest undeveloped resource of critical metals for building infrastructure, power generation, transmission, and batteries, today announced that it will host a conference call on Thursday, March 27, 2025, to provide an update on fourth quarter and full year 2024 financial results and recent corporate developments. Fourth...
Corvus Pharmaceuticals Announces Presentation of Additional Data from ...
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from the Company’s Phase 1/1b clinical trial of soquelitinib for the treatment of patients with T cell lymphoma (TCL) is being presented at the 16th Annual T-Cell L...
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Au...
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 ...
Creative Realities Powers Digital Transformation at Rogers Arena, Mark...
Creative Realities Powers Digital Transformation at Rogers Arena, Marking First Major Canadian Sports & Entertainment Deployment Next-generation IPTV and digital signage make waves at live venues, setting new standards for fan experiences. LOUISVILLE, Ky., March 19, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), a leading provider of digital signage and media solutions, announces the successful modernization of Rogers Arena, home of the Vancouver Canucks, marking the company’s first full-scale deployment in Canada’s IPTV and live venue industry. As part of a broader venue-wide technology refr...
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter a...
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 25, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2024 financial results. The conference call can be access...
Creative Realities Announces Reflect Settlement Agreement
Creative Realities Announces Reflect Settlement Agreement Quantifies Liability and Future Payment Plans LOUISVILLE, Ky., March 17, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and AdTech solutions, today announced that it settled and resolved its dispute with former stockholders of Reflect Systems, Inc. (“Reflect”) related to the Company’s obligation to pay to former Reflect stockholders contingent supplemental cash payments under the terms of the Company’s merger with Reflect (the...
Creative Realities Reports Fiscal 2024 Fourth Quarter Results
Creative Realities Reports Fiscal 2024 Fourth Quarter Results Record Year of Performance; Company on Track for Growth Acceleration LOUISVILLE, Ky., March 14, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced its financial results for the fiscal fourth quarter and year ended December 31, 2024. Highlights: Fourth quarter revenue of $11.0 million versus $14.5 million in the prior-year periodGross profit of $4.9 million for the three months...
Creative Realities, Inc. Announces Fourth Quarter and Full Year 2024 E...
Creative Realities, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call Information LOUISVILLE, Ky., March 13, 2025 (GLOBE NEWSWIRE) -- ("Creative Realities," "CRI," or the "Company") (NASDAQ: ), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the quarter and full year ended December 31, 2024 after the market closes on Friday, March 14, 2025. A conference call to review the results is scheduled for Monday, March 17, 2025, at 9:00 am Eastern Time, which will include prepared re...
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial ...
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the National Institute of A...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.